New Studies Show Clinically Significant Palliation of Painful Spinal Metastases With DFine STAR™ Tumor Ablation System

SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, released results from two studies presented at the Society of Interventional Radiology’s Annual Scientific Meeting. Results from both studies underscore the benefits of advanced Targeted-Radiofrequency Ablation™ (t-RFA) therapy using the STAR™ Tumor Ablation System for the treatment of painful malignant lesions of the vertebral body.